Oncology
Latest news
826 articles · 20 / page
Music Therapy Proves Noninferior to Cognitive Behavioral Therapy for Managing Anxiety in Cancer Survivors: Results from a Randomized Trial
A randomized clinical trial demonstrates that telehealth-delivered music therapy is noninferior to cognitive behavioral therapy for reducing anxiety in cancer survivors, providing durable, clinically meaningful improvements and a viable alt
Industrial Food Preservatives Linked to Increased Cancer Risk: Evidence from the NutriNet-Santé Prospective Cohort
A large-scale prospective study of over 100,000 participants identifies significant associations between specific food preservatives, including sorbates, nitrites, and nitrates, and an increased risk of overall, breast, and prostate cancers
2025 FDA Drug Approvals: A Critical Review of New Therapeutic Frontiers and Regulatory Shifts
A comprehensive analysis of the 46 novel drugs approved by the FDA in 2025, highlighting breakthroughs in oncology, chronic pain, and respiratory medicine, alongside significant regulatory changes and a preview of the 2026 pipeline.
Active Cancer Increases Both Ischemic and Bleeding Risks in Minor Stroke Patients on DAPT: Lessons from the READAPT Study
A secondary analysis of the READAPT study reveals that patients with active cancer or hematological malignancies face significantly higher risks of recurrent stroke and bleeding while on dual antiplatelet therapy (DAPT) compared to those in
Precision Prognosis: Navigating Decision-Making in Head and Neck Cancer Through Individualized Counseling
This review analyzes the impact of individualized prognostic counseling on decisional conflict and regret in patients with head and neck squamous cell carcinoma, highlighting the efficacy of online prognostic tools in fostering shared decis
Neoadjuvant Chemoradiotherapy vs. Surgery with Adjuvant Therapy for ESCC: Five-Year Outcomes Challenge the Universal Standard
A Phase 3 randomized clinical trial finds no significant difference in 5-year overall survival between neoadjuvant chemoradiotherapy and surgery with adjuvant therapy for locally advanced ESCC, emphasizing the need for personalized treatmen
Toripalimab Establishes a New Standard of Care in First-Line Advanced Acral Melanoma: Evidence from the MELATORCH Trial
The Phase 3 MELATORCH trial demonstrates that toripalimab significantly improves progression-free survival (PFS) compared to dacarbazine in patients with advanced acral melanoma, reducing the risk of progression or death by 29.2% with a man
Triple-Drug Regimen with Tiragolumab and Atezolizumab Shows Superior Response in First-Line Esophageal Cancer: The MORPHEUS-EC Trial
The phase 1b/2 MORPHEUS-EC trial demonstrates that adding the anti-TIGIT antibody tiragolumab to atezolizumab and chemotherapy significantly improves objective response rates (67.7%) in patients with previously untreated, locally advanced o
Dual Checkpoint Inhibition: Tiragolumab and Atezolizumab Set New Survival Benchmarks in Advanced Esophageal Squamous Cell Carcinoma
The Phase 3 SKYSCRAPER-08 trial demonstrates that adding the anti-TIGIT tiragolumab and anti-PD-L1 atezolizumab to chemotherapy significantly extends overall survival and progression-free survival in patients with treatment-naive, unresecta
Molecular-Based Adjuvant Therapy Proves Safe and Effective in High-Intermediate Risk Endometrial Cancer: Results from the PORTEC-4a Trial
The PORTEC-4a trial confirms that molecular profiling safely guides adjuvant treatment in high-intermediate risk endometrial cancer, reducing overtreatment by 46% while maintaining non-inferiority in locoregional control compared to standar
Adjuvant Temozolomide for IDH-Mutated Anaplastic Astrocytoma: Final CATNON Results Confirm a Decade of Survival Benefit
The final analysis of the EORTC CATNON trial reveals that 12 cycles of adjuvant temozolomide significantly extend overall survival to 12.5 years in IDH-mutated anaplastic astrocytoma, whereas concurrent temozolomide provides no added clinic
Tailoring Axillary Surgery: Omitting Dissection for Residual Micrometastases After Neoadjuvant Chemotherapy
The OPBC-07/microNAC study suggests that axillary lymph node dissection can be safely omitted in many breast cancer patients with residual micrometastases post-neoadjuvant chemotherapy, provided nodal radiotherapy is used, though triple-neg
Immunotherapy Challenges in Metastatic Castration-Resistant Prostate Cancer: An In-Depth Analysis of the CheckMate 7DX Phase 3 Trial
CheckMate 7DX demonstrates that adding nivolumab to docetaxel fails to improve survival outcomes in ARPI-pretreated, chemotherapy-naive mCRPC, while significantly increasing toxicity and treatment-related mortality.
Ideal Cardiovascular Health Scores Linked to 38% Lower Mortality in Cancer Survivors: Insights from the Moli-sani Study
A longitudinal study of cancer survivors reveals that those maintaining ideal cardiovascular health, measured by the Life’s Simple 7 metric, significantly reduce their risk of all-cause and cancer-specific mortality through pathways involvi
Medical Cannabis as an Opioid-Sparing Strategy: Evidence from Chronic and Cancer Pain Populations
This review synthesizes recent evidence from large-scale cohorts and synthetic control studies, demonstrating that medical cannabis participation and dispensary availability are significantly associated with reduced opioid prescriptions and
High Efficacy of Pemigatinib in Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement: Insights from the FIGHT-203 Trial
The FIGHT-203 phase 2 trial demonstrates that pemigatinib, a selective FGFR inhibitor, induces high rates of complete clinical and cytogenetic responses in patients with FGFR1-rearranged myeloid/lymphoid neoplasms, offering a potent targete
Lay Health Worker-Led Symptom Monitoring Slashes Acute Care Use and Costs in Older Cancer Patients
A multisite RCT published in JAMA reveals that lay health worker-led symptom assessments for older adults with cancer significantly reduce emergency department visits, hospitalizations, and healthcare costs, offering a scalable model for ge
Peg-GCSF Primary Prophylaxis Effectively Mitigates Severe Neutropenia and Enhances Quality of Life in mFOLFIRINOX-Treated Pancreatic Cancer
A randomized phase 2 trial demonstrates that primary prophylaxis with peg-GCSF significantly reduces grade 3-4 and febrile neutropenia in patients with unresectable pancreatic cancer receiving mFOLFIRINOX, while improving patient-reported q
Rare but Severe: Characterizing Immune Checkpoint Inhibitor-Induced Diabetes in 13,966 Trial Participants
A large-scale NCI study reveals that while immune checkpoint inhibitor-induced diabetes is rare (0.52%), it is highly morbid, often requiring hospitalization or ICU care. Risk varies significantly by treatment regimen, with combination immu
Beyond a Symptom: Baseline Fatigue as a Clinical Biomarker for Severe and Fatal Cancer Treatment Toxicities
A large-scale pooled analysis of 17 SWOG trials demonstrates that baseline patient-reported fatigue significantly increases the risk of severe, life-threatening, and fatal toxic effects from systemic cancer therapy, highlighting its role as
Browse by specialty
Open language-specific specialty feeds and department pages.